Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia

Foresee Pharmaceuticals announced that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study currently being initiated, at the Fanconi Anemia...

Related Keywords

Sheraton , British Columbia , Canada , Vancouver , , Fanconi Anemia Research Fund , Memorial Sloan Kettering Cancer Center , Stanford University , University Of Minnesota , Foresee Pharmaceuticals , Clinical Trial Evaluating , Biological Activity , Fanconi Anemia , Fuschia Phase , Sheraton Vancouver , Grand Ballroom , Aldehyde Dehydrogenase , Markets ,